Stockhub

Oncolytics Biotech Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

(newest | oldest) View ( | older 50) (20 | 50 | 100 | 250 | 500)

20 July 2023

20 August 2022

13 August 2022

30 July 2022

  • curprev 18:0318:03, 30 July 2022‎ Chris talk contribs‎ 710 bytes +710‎ Created page with "Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab,..." Tag: Visual edit
(newest | oldest) View ( | older 50) (20 | 50 | 100 | 250 | 500)
Retrieved from ‘https://stockhub.co/research/Oncolytics_Biotech_Inc.’